Naftifine 1% cream once or twice daily vs placebo cream once or twice daily: Recurrence
Naftifine 1% cream once or twice daily showed no clear difference in relapse or recurrence Evidence of clinical or mycological infection… compared with placebo cream once or twice daily (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Naftifine 1% cream once or twice daily vs placebo cream once or twice daily Relapse or recurrence Evidence of clinical or mycological infection in previously cured participants · patients with tinea cruris and tinea corporis Naftifine 1% cream once or twice daily showed no clear difference in relapse or recurrence Evidence of clinical or mycological infection… compared with placebo cream once or twice daily (low certainty). Topical antifungal treatments for tinea cruris and tinea corporis (2014) · Cochrane Headline outcomes only | RR 0.07 [0, 1.25] | 1 study · 44 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Topical antifungal treatments for tinea cruris and tinea corporis 2014 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.